| Literature DB >> 29507418 |
Louise Dubuisson1,2, Florence Lormières1,2, Stefania Fochi3, Jocelyn Turpin1,2, Amandine Pasquier1,2, Estelle Douceron1,2, Anaïs Oliva1,2, Ali Bazarbachi4,5, Valérie Lallemand-Breitenbach6, Hugues De Thé6, Chloé Journo7,8, Renaud Mahieux9,10.
Abstract
Since the identification of the antisense protein of HTLV-2 (APH-2) and the demonstration that APH-2 mRNA is expressed in vivo in most HTLV-2 carriers, much effort has been dedicated to the elucidation of similarities and/or differences between APH-2 and HBZ, the antisense protein of HTLV-1. Similar to HBZ, APH-2 negatively regulates HTLV-2 transcription. However, it does not promote cell proliferation. In contrast to HBZ, APH-2 half-life is very short. Here, we show that APH-2 is addressed to PML nuclear bodies in T-cells, as well as in different cell types. Covalent SUMOylation of APH-2 is readily detected, indicating that APH-2 might be addressed to the PML nuclear bodies in a SUMO-dependent manner. We further show that silencing of PML increases expression of APH-2, while expression of HBZ is unaffected. On the other hand, SUMO-1 overexpression leads to a specific loss of APH-2 expression that is restored upon proteasome inhibition. Furthermore, the carboxy-terminal LAGLL motif of APH-2 is responsible for both the targeting of the protein to PML nuclear bodies and its short half-life. Taken together, these observations indicate that natural APH-2 targeting to PML nuclear bodies induces proteasomal degradation of the viral protein in a SUMO-dependent manner. Hence, this study deciphers the molecular and cellular bases of APH-2 short half-life in comparison to HBZ and highlights key differences in the post-translational mechanisms that control the expression of both proteins.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29507418 DOI: 10.1038/s41388-018-0163-x
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867